Report overview
hosphorus is an important element for normal physiologic functions such as bone construction, nerve function, and muscle contraction. About 85% of phosphorus is stored in the bones and different tissues in the body. The excess phosphorus is eliminated from the body by the urinary system. The normal phosphate level in the blood is 3-4 mg/dL. Electrolytic disturbance resulting in high levels of phosphate in the blood causes hyperphosphatemia. Individuals with chronic kidney diseases have a decreased glomerular filtration rate and increased serum phosphate levels. The high phosphate levels in the serum lower calcium levels because of phosphate precipitation by calcium ions, leading to calcification of vascular tissues and heart diseases. Aluminum-, calcium-, magnesium-, and iron-based and aluminum-free, calcium-free phosphate binders are used to treat the condition.
This report aims to provide a comprehensive presentation of the global market for Hyperphosphatemia Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hyperphosphatemia Drugs. This report contains market size and forecasts of Hyperphosphatemia Drugs in global, including the following market information:
Global Hyperphosphatemia Drugs Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Hyperphosphatemia Drugs Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five Hyperphosphatemia Drugs companies in 2022 (%)
The global Hyperphosphatemia Drugs market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Major factors driving the market include rise in prevalence of chronic diseases, high unmet medical needs, increase in the number of people undergoing dialysis, large geriatric population, and surge in public awareness worldwide. Diabetes and hypertension are the main causes of renal failure, which leads to hyperphosphatemia. However, stringent regulations by regulatory bodies such as the Food and Drug Administration (FDA), non-adherence to treatment regimens, and rise in side effects of hyperphosphatemia drugs are likely to inhibit the market. According to FDA use of hyperphosphatemia drugs for the treatment of high or low phosphorus levels in the human body is neither safe nor effective. High growth potential in untapped economies, such as India, China, South Africa, and Brazil, is expected to create lucrative opportunities for key players. Rise in geriatric population and increase in cases of osteoporosis in Asia Pacific is anticipated to drive the market. Osteoporosis is often undertreated and underdiagnosed, which is driving the hyperphosphatemia drugs market in Asia Pacific. The available calcium, lanthanum, sevelamer, and iron-based drugs for treating hyperphosphatemia are associated with certain side effects. The long-term use of calcium-based drugs such as calcium carbonate and calcium acetate can cause vascular calcification.
We surveyed the Hyperphosphatemia Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Hyperphosphatemia Drugs Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Hyperphosphatemia Drugs Market Segment Percentages, by Type, 2022 (%)
Aluminum Phosphate Binder
Iron Phosphate Binder
Magnesium Phosphate Binder
Calcium Phosphate Binder
Global Hyperphosphatemia Drugs Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Hyperphosphatemia Drugs Market Segment Percentages, by Application, 2022 (%)
Hospitals
Clinics
Others
Global Hyperphosphatemia Drugs Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Hyperphosphatemia Drugs Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Hyperphosphatemia Drugs revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Hyperphosphatemia Drugs revenues share in global market, 2022 (%)
Key companies Hyperphosphatemia Drugs sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Hyperphosphatemia Drugs sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Keryx Biopharmaceuticals
Sanofi
Takeda
Vifor Pharma
Amgen
Bayer
Outline of Major Chapters:
Chapter 1: Introduces the definition of Hyperphosphatemia Drugs, market overview.
Chapter 2: Global Hyperphosphatemia Drugs market size in revenue and volume.
Chapter 3: Detailed analysis of Hyperphosphatemia Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Hyperphosphatemia Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Hyperphosphatemia Drugs capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
